Permission granted by Biogen
A make-or-break moment is quickly approaching for what some consider the world s most closely watched experimental medicine. By June 7, the Food and Drug Administration should decide whether to approve or reject aducanumab, a potentially first-of-its-kind therapy meant to slow the progression of Alzheimer s disease.
The FDA s verdict is far from certain. The data supporting aducanumab are complex and controversial. Alzheimer s experts remain torn on whether the drug actually improves patients lives. Even the FDA s internal staff are divided about the prospect of approval.
However the agency ultimately leans, its decision will have significant impacts on both Alzheimer s care as well as aducanumab s developers, Biogen and Eisai.